上海交通大学学报(医学版)

• 论著(临床研究) • 上一篇    下一篇

不同类型TNF拮抗剂治疗强直性脊柱炎发生不良反应的临床分析

周兰兰,丁 玉   

  1. 南京医科大学 第一附属医院风湿免疫科, 南京 210029
  • 出版日期:2013-12-28 发布日期:2014-01-02
  • 通讯作者: 丁 玉, 电子信箱: 18951085815@189.cn。
  • 作者简介:周兰兰(1983—), 女, 硕士生; 电子信箱: zllfsmyk@163.com。

Clinical analysis of adverse reactions of ankylosing spondylitis patients treated by different TNF-inhibitors

ZHOU Lan-lan, DING Yu   

  1. Department of Rheumatology, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
  • Online:2013-12-28 Published:2014-01-02

摘要:

目的 观察采用不同结构和人源化程度的肿瘤坏死因子(TNF)拮抗剂治疗强直性脊柱炎过程中不良反应的发生情况。方法 收集接受TNF拮抗剂治疗的180例强直性脊柱炎患者的资料,了解不同生物结果TNF拮抗剂的分布,观察患者不良反应的发生和治疗情况。结果 分别选用3种不同结构和人源化程度的TNF拮抗剂进行治疗,其中50例患者使用英夫利昔单抗(人鼠嵌合单抗,静脉给药),50例患者使用阿达木单抗(全人源化单抗,皮下注射),80例患者使用依那西普(进口和国产,均为皮下注射)。3种TNF拮抗剂治疗过程中均有不良反应发生,英夫利昔单抗、依那西普(国产)、依那西普(进口)和阿达木单抗不良反应的发生率分别为14%、13%、4%、6%;全人源化TNF拮抗剂总体安全性优于人鼠嵌合的TNF拮抗剂。结论 相较于全人源化TNF拮抗剂,人鼠嵌合抗体更易诱发不良反应,可能与其免疫原性有关,在使用中必
须严格观察和处理。

关键词: 肿瘤坏死因子拮抗剂, 强直性脊柱炎, 不良反应

Abstract:

Objective To study immunologic mechanisms induced by different TNF-inhibitors in ankylosing spondylitis treatment. Methods A total of 180 patients with ankylosing spondylitis received TNF-α inhibitors were collected. Distribution of different TNF-inhibitors and adverse reactions of patients were observed. Results Three kinds of TNF-inhibitors were used. Among the patients, 50 were treated with Infliximab; 50, with Adalimumab; and 80, with Etanercept. The adverse reaction rates were 14%, 13%, 4%, and 6% in Infliximab, Etanercept (domestic), Etanercept (imported), and Adalimumab, respectively. The humanized TNF-inhibitor was safer than the human-mouse chimeric TNF-inhibitor. Conclusion The human-mouse chimeric TNF-inhibitor was more likely to induce adverse reactions, which might be related to its immunogenicity.

Key words: TNF-inhibitor, ankylosing spondylitis, adverse reactions